Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Upstream Bio, Inc.NASDAQ: UPB
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$95.61M, compared with -$69.61M a year earlier.
Context
- Net debt amounted to 30.1% of total assets at the end of Q1 FY2026, up 14.8 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -37.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (100.31M) USD
- Year-over-year change
- +69.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (100.31M) | +69.0% |
| FY2024 | 2024-12-31 | (324.06M) | -1156.6% |
| FY2023 | 2023-12-31 | (25.79M) | -52.1% |
| FY2022 | 2022-12-31 | (16.96M) | — |
Net Debt vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -37.3% is the 8th highest of 10, against a peer median of -7.3%.
- Net debt amounts to 30.1% of total assets for UPB, versus a peer median of 19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $214.47M USD | +241.0% | — | 45.4% | |
| Mar 2026 | $66.7M USD | +292.3% | — | 6.4% | |
| Mar 2026 | -$54.21M USD | -610.7% | — | 7.1% | |
| Sep 2026 | -$82.73M USD | -27.5% | — | 7.5% | |
| Jun 2026 | -$90.53M USD | -13.5% | — | 9.4% | |
UPBUpstream Bio, Inc. | Mar 2026 | -$95.61M USD | -37.3% | — | 30.1% |
| Mar 2026 | -$148.5M USD | +24.0% | — | 19.9% | |
| Sep 2026 | -$235.15M USD | -7.3% | — | 29.9% | |
| Sep 2026 | -€282.13M EUR | +14.2% | — | 95.6% | |
| Mar 2026 | -$528.88M USD | -141.0% | — | 90.6% | |
| Peer median (excluding UPB) | — | -7.3% | — | 19.9% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.